ReviewBMC medicine2013
The sweet and sour of serological glycoprotein tumor biomarker quantification.
Review in BMC medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.International journal of molecular sciences · 2021Pooled it
- LeGenD: High-throughput N-glycan profiling using explainable AI and lectin profiling.The Journal of biological chemistry · 2026Article
- Quantitative site-specific N-glycosylation analysis reveals IgG glyco-signatures for pancreatic cancer diagnosis.Clinical proteomics · 2024Article
- Development of a first-in-class antibody and a specific assay for α-1,6-fucosylated prostate-specific antigen.Scientific reports · 2024Article
- A compact microfluidic laser-induced fluorescence immunoassay system using avalanche photodiode for rapid detection of alpha-fetoprotein.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
- LeGenD: determining N-glycoprofiles using an explainable AI-leveraged model with lectin profiling.bioRxiv : the preprint server for biology · 2024Article
- Article
- Comparative site-specific N-glycoproteome analysis reveals aberrant N-glycosylation and gives insights into mannose-6-phosphate pathway in cancer.Communications biology · 2023Article
- Preparation of IgG imprinted polymers by metal-free visible-light-induced ATRP and its application in biosensor.Talanta · 2021Article
- Glycomic-Based Biomarkers for Ovarian Cancer: Advances and Challenges.Diagnostics (Basel, Switzerland) · 2021Review
- POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer.Translational oncology · 2021Article
- Review
- Aptamers targeting protein-specific glycosylation in tumor biomarkers: general selection, characterization and structural modeling.Chemical science · 2020Article
- Aberrant sialylation in ovarian cancers.Journal of the Chinese Medical Association : JCMA · 2020Review
- Preparation and Nanoencapsulation of Lectin fromBioMed research international · 2020Article
- Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.Current protocols in protein science · 2019Article
- Glycosylation and its implications in breast cancer.Expert review of proteomics · 2019Review
- A Novel Mass Spectrometry Platform for Multiplexed N-Glycoprotein Biomarker Discovery from Patient Biofluids by Antibody Panel Based N-Glycan Imaging.Analytical chemistry · 2019Article
- N-glycan microheterogeneity regulates interactions of plasma proteins.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera.Oncology reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant and dysregulated protein glycosylation is a well-established event in the process of oncogenesis and cancer progression. Years of study on the glycobiology of cancer have been focused on the development of clinically viable diagnostic applications of this knowledge. However, for a number of reasons, there has been only sparse and varied success. The causes of this range from technical to biological issues that arise when studying protein glycosylation and attempting to apply it to practical applications. This review focuses on the pitfalls, advances, and future directions to be taken in the development of clinically applicable quantitative assays using glycan moieties from serum-based proteins as analytes. Topics covered include the development and progress of applications of lectins, mass spectrometry, and other technologies towards this purpose. Slowly but surely, novel applications of established and development of new technologies will eventually provide us with the tools to reach the ultimate goal of quantification of the full scope of heterogeneity associated with the glycosylation of biomarker candidate glycoproteins in a clinically applicable fashion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.